When Strangers Deliver Bad News to Patients All too often, I end up giving prognoses to patients I barely know Jan 31, 2022
Dual HER2 Therapy Active in Previously Treated Lung Cancer Disease control in 87% of HER2-mutant NSCLC treated with trastuzumab, pertuzumab, docetaxel Jan 27, 2022
An 'Intriguing Failure' in Advanced, Pre-Treated GIST Second-line ripretinib unable to best sunitinib, but still had meaningful clinical activity Jan 26, 2022
Trial Data Confirm Heightened Risks With JAK Inhibitor May help patients and clinicians better weigh benefit against adverse effects Jan 26, 2022
Paclitaxel-Carboplatin Established as Standard of Care for Uterine Carcinosarcoma Median OS and PFS improved versus paclitaxel-ifosfamide Jan 25, 2022
GICS Roundup: PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancer Plus: Promising activity in BRAF-mutant CRC, L-asparaginase drug falls short in pancreatic cancer Jan 24, 2022
Adagrasib Promising in KRAS-Mutant GI Cancers The KRAS G12C inhibitor showed a disease control rate of 100% in small study Jan 24, 2022
Survival Bump in Biliary Cancer With Immunotherapy Plus Chemotherapy Adding durvalumab boosts OS by 1.3 months, first survival improvement in a decade Jan 23, 2022
Immunotherapy Not Additive to Standard of Care for Untreated Metastatic CRC No difference in survival outcomes with add-on nivolumab to chemo, bevacizumab Jan 23, 2022
Potential New First-Line Options for Unresectable Hepatocellular Carcinoma Tremelimumab-durvalumab improves OS, single-agent durvalumab non-inferior to sorafenib Jan 22, 2022
Pre-Op Immunotherapy Combo Makes Headway in Select Gastric Cancers Plus, novel bispecific antibody tested as first-line therapy for advanced gastric/GEJ cancer Jan 21, 2022
More Data for Upfront PD-1 Inhibition in Gastric, Esophageal Cancer Updates from two landmark trials show consistent benefits across subgroups, PD-L1 expression Jan 21, 2022
We've Never Really Understood the Prostate Wolinsky reviews Ericka Johnson's new book, A Cultural Biography of the Prostate Jan 19, 2022
Growing Controversy Over 'Skinny' Labeling for Generic Drugs What's at stake in legal battles over patent-avoiding approval pathway for generics Jan 17, 2022
Active Surveillance for Melanoma Meets Reality of Loss to Follow-Up More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
Earlier Colorectal Screening Bolstered by Real-World Data Researchers of a national registry study say "45 is now the new 50" Jan 10, 2022
Melanoma Patient on Immunotherapy Develops Severe Dermatitis Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
Older Patients With Low-Risk DCIS May Not Benefit From Surgery, Radiation Low rate of invasive recurrence, benefits of surgery and RT limited to patients under 70 Jan 05, 2022
Finally, a 'New Standard' for Severe Aplastic Anemia After 3 decades of failures, RACE trial shows superiority of new first-line regimen Jan 05, 2022
Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survival Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
In Early Prostate Cancer, Black Men Do Better With Radiotherapy Than White Men "Unexpected" finding holds even though Black men are more likely to have high-risk features Dec 29, 2021
Living History: 50 Years After the Birth of National Cancer Centers New book examines the progress 50 years following the National Cancer Act of 1971 Dec 22, 2021
Trifluridine/Tipiracil Combination Misses Mark in Metastatic Colon Cancer No improvement in PFS versus standard for older patients ineligible for intensive therapy Dec 21, 2021
Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemia OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
Virgil Abloh's Cardiac Angiosarcoma The fashion designer's death due to this rare form of cancer took the world by surprise Dec 15, 2021
Gene Therapy Resolves Severe Pain Events in Sickle Cell Disease LentiGlobin also normalized hemoglobin and reduced hemolysis markers Dec 15, 2021
Can Dasatinib Dose Be Halved in Low-Risk CML? Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/B Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
In the Story of Our Practice, We're Always the Hero When is it right to challenge our medical colleagues? Dec 14, 2021
R-CHOP Toppled in First-Line DLBCL Trial Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
Ξ²-Thalassemia Patients Go Transfusion-Free With Gene Therapy Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
R2 Maintenance for Elderly MCL Patients Worth the Risk? Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer No clear explanation for responses to HER2-targeted drug in HER2-negative tumors Dec 12, 2021
Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancer Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors Dec 12, 2021
